FDA plans ultra-fast review of three psychedelic drugs following Trump directive

Chronological Source Flow
Back

AI Fusion Summary

The FDA announced ultra‑fast review for three psychedelic drugs targeting hard‑to‑treat mental health conditions, including depression, following President Trump’s executive order to accelerate access and relax restrictions. Priority review vouchers were awarded to two psilocybin developers and one methylone developer.
#FDA #TRUMP #PSILOCYBIN #METHYLONE #PHASE_III #MENTAL_HEALTH #ULTIMATE_REVIEW
24/04 17:04 wdrb.com
6 Πηγές

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

POLITICS
24/04 17:16 washingtontimes.com

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

POLITICS
24/04 17:22 whdh.com

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

POLITICSNEWS
24/04 17:45 adn.com

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

POLITICS
24/04 17:45 washingtonexaminer.com

FDA fast-tracks psychedelic drug research following Trump executive order

DONALD TRUMPMENTAL HEALTHWASHINGTON D.C.VETERANSEARTHQUAKEHEALTHCARE
24/04 18:30 newsweek.com

Trump Order Spurs FDA to Speed Reviews of Psychedelic Therapies

POLITICS
Comments
Loading...
0